Orsiro Mission Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System
Biotronik AG · Decision date Aug 19, 2025
What did the FDA approve?
FDA records P170030/S055 as a supplement to PMA P170030, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 19, 2025.
FDA approval order statement
approval to introduce an additional trade name, Synsiro Pro, for the approved PMA device.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 19, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P170030/S055
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik AG
- Product code
- NIQ
- Decision code
- APPR
- Decision date
- Aug 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Biotronik AG
- Product code
- NIQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170030 · Original PMA
ORSIRO Sirolimus Eluting Coronary Stent System
P170030/S055 received
Application receipt date recorded by FDA.
P170030/S055 · FDA decision
Real-Time Process
P170030/S056 · Related supplement
Orsiro Mission Sirolimus Eluting Coronary Stent System
P170030/S059 · Related supplement
Orsiro Mission Sirolimus Eluting Coronary Stent System, Synsiro Pro Sirolimus Eluting Coronary Stent System
P170030/S060 · Related supplement
Orsiro Mission Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System
P170030/S061 · Related supplement
ORSIRO Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System
P170030/S047 · Related supplement
Orsiro Mission Sirolimus Eluting Coronary Stent System
P170030/S062 · Related supplement
ORSIRO Sirolimus Eluting Coronary Stent System
P170030/S052 · Related supplement
Orsiro Mission Sirolimus Eluting Coronary Stent System
P170030/S058 · Related supplement
Orsiro Mission Sirolimus Eluting Coronary Stent System
P170030/S064 · Related supplement
Orsiro Mission larger diameter stents Ø 4.5 5.0 mm
P170030/S065 · Related supplement
ORSIRO Sirolimus Eluting Coronary Stent System
P170030/S066 · Related supplement
ORSIRO Sirolimus Eluting Coronary Stent System
Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik AG | PMA approval | Feb 22, 2019 | FDA | |
| Biotronik AG | PMA supplement | Oct 10, 2025 | FDA | |
| Biotronik AG | PMA supplement | Feb 20, 2026 | FDA | |
| Biotronik AG | PMA supplement | Feb 22, 2026 | FDA | |
| Biotronik AG | PMA supplement | Apr 1, 2026 | FDA | |
| Biotronik AG | PMA supplement | Apr 15, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S062 | Biotronik AG | PMA supplement | Apr 15, 2026 | FDA |
| Biotronik AG | PMA supplement | Jun 5, 2026 | FDA | |
| Biotronik AG | PMA supplement | Jun 11, 2026 | FDA | |
| Biotronik AG | PMA supplement | Jul 23, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S065 | Biotronik AG | PMA supplement | Aug 7, 2026 | FDA |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Aug 28, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA | |
| Medtronic Vascular | PMA supplement | Aug 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P170030/S055
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






